ClinicalTrials.gg
Sign In
Active, not recruitingNCT07870954Updated Oct 13, 2026

Comparative Study Between the Effects of Deep Versus Moderate Neuromuscular Blockade on Postoperative Recovery and Immune Function in Patients Undergoing Total Hip Replacement Surgery.

An interventional study of ToF ( Train of Four) Scan in Immune Responses and Post Operative Recovery, sponsored by Sohag University. Active, not recruiting at 1 site in Egypt. Open to participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sohag University · Not applicable, Interventional, and Health services research

Updated Oct 13, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
16 Years to 60 Years
Sex
All
01

Study summary

. The investigators hypothesized that DNMB ( Deep NeuroMuscular Block) would yield superior postoperative recovery quality and attenuate the surgery-induced immune suppression compared to MNMB ( Moderate NeuroMuscular Block)in patients undergoing THA (Total Hip Arthroplasty).

02

Conditions studied

  • Immune Responses
  • Post Operative Recovery
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,220 studies on the registry; 629 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (ASA physical status I-III).
  • Elective, primary THA under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • Neuromuscular disease.
  • Renal/hepatic impairment.
  • Allergy to NMBAs or reversal agents.
  • Pregnancy.
  • Chronic opioid use.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    DNMB ( Deep NeuroMuscular Block) Group

    Device: ToF ( Train of Four) Scan

  • Placebo comparator
    MNMB ( Moderate NeuroMuscular Block) Group

    Device: ToF ( Train of Four) Scan

Interventions

  • DeviceToF ( Train of Four) Scan

    Depth of NMB will be monitored continuously using the ToFScan. The target NMB depth will be maintained until skin closure

06

What researchers measure

Primary outcomes

  1. Quality of Recovery-15 (QoR-15)

    questionnaire score at 24 hours postoperatively with higher scores to be better outcomes

    Time frame: 24 hours post operative

Secondary outcomes

  1. Recovery Metrics

    \- Time to meet modified Aldrete score ≥9 in PACU.

    Time frame: immediately after surgery. With higher scores above 9 to be with better outcomes

  2. Immune Functions

    Time frame: measured perioperatively ( preoperative and at 24/48 hours postoperatively) With higher scores above normal range for each indicates worse outcomes.

  3. Innate immune function biomarkers

    Time frame: measured preoperatively and at 24/48 hours postoperatively

  4. postoperative complications

    Time frame: 30 days post operative

07

Study locations

1 site
  • Faculty of Medicine, Sohag University
    Sohag, Egypt
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 14, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Nov 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2026
First posted
Oct 13, 2026
StartActual
Jun 20, 2026
Primary completionEst.
Nov 20, 2026
CompletionEst.
Dec 20, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07870954
Lead sponsor
Sohag University
Responsible party
Islam Mokhtar Ahmed (Assistant Professor of Anesthesia and Intensive Care, Sohag University) — Principal investigator
First posted
Oct 13, 2026
Start date
Jun 20, 2026
Primary completion
Nov 20, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Sohag University →

Start the discussion